IN SILICO ANALYSIS AND MOLECULAR DOCKING STUDIES OF RH1 DRUG WITH UPREGULATED KINASES IN RH1 RESISTANCE HUMAN BREAST CANCER CELL LINE MDA-MB231.

Pramodkumar P. Gupta1, 2, 3, Dalius Kučiauskas1, Shanker Lal Kothari3, Virupaksha A. Bastikar1, 4, Mindaugas Valius1

1 Institute of Biochemistry, Vilnius University, Vilnius, Lithuania

2 School of Biotechnology and Bioinformatics, D Y Patil University, Navi Mumbai 400614, Maharastra, India.

3 Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur -303002, Rajasthan, India.

4 Amity Institute of Biotechnology Amity University, Mumbai - Pune Expressway, Bhatan, Post – Somathne, Panvel, Mumbai, Maharashtra 410206, India.

Identification of potential drug targets is a critical step towards the understanding of drug activity, improvement in the drug's therapeutic management and its therapeutic potential. In the last few years a pharmacological interest was developed on targeted therapies as a more specific and effective way for stopping cancer progression. Aziridinylquinone RH-1 is a potential anticancer agent which was developed to be activated by NAD (P) H: quinone oxidoreductase (NQO1) which reduces RH1 into DNA-alkylating hydroquinone and is overexpressed in many tumors. Another suggested mechanism of RH-1 toxicity is the formation of reactive oxygen species (ROS) arising from its redox cycling.

In this research we cultivated MDA-MB231 cell in the presence of RH1 to generate RH1 resistant cell line and used multiplexed kinase inhibitor beads (MIBs) and quantitative mass spectrometry analysis to compare kinase activity in parental and RH1 resistant MD-MDA-231 cell line of triple negative breast cancer. Using MIB/MS data, activity changes of over 150 kinases were quantitatively measured from various protein kinase families. We hypothesize that the observed change in kinase activity drives an off-target mechanism for RH1 activity. It is has been already shown that NQO1 can act as kinase inhibitors famitinib and 5-hydroxyl-defluorofamitinib (active form). NQO2 can be inhibited by serine-threonine kinase CK2 inhibitors and tyrosine kinase inhibitors Imatinib and Nilotinib.

Applying the rationale method of Computer Aided Drug Discovery (CADD), a comparative molecular docking study has been carried out between the kinase structures with their known, experimental inhibitors and RH1 drug.Our analysis show that casein kinase I isoform alpha (CSNK1A1), serine/threonine-protein kinase Chk1 (CHEK1), ribosomal protein S6 kinase alpha-3 (RPS6KA3), ephrin type-A receptor 3 (EPHA3), mast/stem cell growth factor receptor Kit (KIT) and dual specificity protein kinase TTK (TTK) show a highly similar and identical pharmacophoric interaction between RH1 and their indigenous inhibitors with comparable binding energies.